Ultragenyx Pharmaceutical (RARE) Free Cash Flow (QoQ) (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) Free Cash Flow (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.71 Bn | 2.30 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.49% |
| Dec 31, 2025 | -8.70% |
| Sep 30, 2025 | 16.88% |
| Jun 30, 2025 | 33.21% |
| Mar 31, 2025 | -90.91% |
| Dec 31, 2024 | -19.94% |
| Sep 30, 2024 | 4.76% |
| Jun 30, 2024 | 60.11% |
| Mar 31, 2024 | -273.33% |
| Dec 31, 2023 | 57.69% |
| Sep 30, 2023 | 6.56% |
| Jun 30, 2023 | 28.48% |
| Mar 31, 2023 | 2.22% |
| Dec 31, 2022 | -253.18% |
| Sep 30, 2022 | 51.31% |
| Jun 30, 2022 | 27.74% |
| Mar 31, 2022 | -818.89% |
| Dec 31, 2021 | 79.69% |
| Sep 30, 2021 | 6.11% |
| Jun 30, 2021 | 51.40% |